National Resilience
San Diego, CA · Boston, MA · RTP, NC · Philadelphia, PA
9 confirmed programs
· 8 sponsors
· Last scored 2026-04-02
73.3
Signal Score
✓ FDA Inspections (1)
✓ Clinical Trials (9)
○ SEC Filings
○ Press
○ EMA GMP
○ MHRA GMP
Quick Facts: National Resilience
- Signal Score
- 73.3/100 (as of 2026-04-02)
- Quality Compliance
- 97.6/100
- Headquarters
- San Diego, CA · Boston, MA · RTP, NC · Philadelphia, PA
- Modalities
- mRNA, Gene Therapy, Cell Therapy
- Active Programs
- 9 confirmed from ClinicalTrials.gov across 8 sponsors
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
Signal Score & Pillar Breakdown
Quality Compliance
97.6
FDA Inspections1 on record
Warning Letters0
Last InspectionVoluntary Action Indicated (VAI) (2025-01-21)
Operations
58.3
9 active programs across 8 sponsors
Modalities: Gene Therapy, Cell Therapy, mRNA
3 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov
9 active programs across 8 sponsors · Modalities: Gene Therapy, Cell Therapy, mRNA · 3 programs in advanced phases (Phase 2/3)
Programs
9
Sponsors8
ModalitiesmRNA, Gene Therapy, Cell Therapy
9 active programs across 8 sponsors
Modalities: Gene Therapy, Cell Therapy, mRNA
3 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov facility matching
Source: ClinicalTrials.gov · Retrieved Apr 05, 2026
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
63.0
3 manufacturing sites
Sites: Research Triangle Park, NC, Boston, MA, San Diego, CA
Source: SEC EDGAR, press monitoring, company profiles
3 manufacturing sites
StatusAvailable
3 manufacturing sites
Sites: Research Triangle Park, NC, Boston, MA, San Diego, CA
3 manufacturing sites
FDA Inspection History
2025-01
NAI
VAI
OAI
| Date | Site | Type | Observations | Classification |
|---|---|---|---|---|
| 2025-01-21 | West Chester, Ohio | Drug Quality Assurance | Yes | Voluntary Action Indicated (VAI) |
Source: FDA Data Dashboard · Retrieved Apr 05, 2026
Clinical Activity 9 studies
NCT07190755
Impact of Patient-Reported Outcomes for Symptom Monitoring in Patients...
NA
Recruiting
NCT06364631
CARE1 Pragmatic Clinical Trial
PHASE3
Recruiting
NCT06072612
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced...
PHASE3
Recruiting
NCT05835895
Safety and Pharmacodynamics of GNSC-001 Intra-articular Injection for Knee...
PHASE1
Active Not Recruiting
NCT05298293
Electronic MonitorIng of Events for dIffuse Large b Cell LYmphoma
NA
Not Yet Recruiting
NCT04023071
FT516 in Subjects With Advanced Hematologic Malignancies
PHASE1
Terminated
NCT04093622
Long-term Follow-Up Study Following Treatment With Fate Therapeutics'...
NA
Terminated
NCT00073463
Safety and Efficacy of Recombinant Adeno-Associated Virus Containing the...
PHASE2/PHASE3
Terminated
NCT03601442
CTL019 Out of Specification MAP for ALL or DLBCL Patients
NA
Available
Source: ClinicalTrials.gov · Retrieved Apr 05, 2026
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Merck KGaA / MilliporeSigma (CDMO)
Darmstadt, DE · St. Louis, MO
Signal Score: 81.8
mRNA, Biologics, Cell Therapy
Cytiva (Mfg Services)
Marlborough, MA · Uppsala, SE
Signal Score: 74.0
Cell Therapy, AAV, mRNA
Lonza Biologics
Houston, TX · Portsmouth, NH · Geleen, NL · Basel, CH
Signal Score: 73.8
AAV, Lentiviral, Cell Therapy, mRNA
NegotiumBio LLC & GmbH
Basel, Switzerland (GmbH) / Greater Boston, MA (LLC)
Small Molecules, Biologics, Cell Therapy, Gene Therapy, CAR-T, Viral Vectors, Oligonucleotides
Danaher (CGT Portfolio)
Washington, DC
Signal Score: 81.5
Cell Therapy, AAV, mRNA